@neurologylive.bsky.social🧠 Satralizumab (Enspryng) reduced relapse risk by 68% vs placebo in the phase 3 METEOROID trial in relapsing MOGAD
📊 At 48 weeks, 87.3% of patients receiving satralizumab remained relapse-free vs 66.5% with placebo
🔬 Findings from #CNS2026: www.neurologylive.com/view/satrali...
#MOGAD #Neurology
@themogproject.bsky.socialNew in Neurology: 312 children with #MOGAD. IVIG was the only treatment linked to fewer relapses (46% lower risk). Observational, so trials are still needed. Congrats Dr. Akash Virupakshaiah and team! 🩵
https://www.neurology.org/doi/10.1212/WNL.0000000000218508
@thesumairafdn.bsky.socialWhat happens after a #MOGAD attack? A new Frontiers in Neurology review explores relapse prevention, steroid tapering, symptom management & emerging treatments.
TSF funded the paper’s publication fees to support access to research.
📖 Read: doi.org/10.3389/fneu...
@themogproject.bsky.socialThe MOG Project is a proud supporter of this year's Rare Neuroimmune Disorders Symposium, hosted by the SRNA. And it's just a few days away!
Learn from leading experts and connect with the global rare neuroimmune community — online + in Dallas.
Register ➡️ srna.ngo/2026-rnds
@themogproject.bsky.socialIt’s World Mental Health Day, and our Family Bulletin’s second edition is here 🩷🩵
Expert advice for parents on behavior changes and burnout, plus real stories from kids and teens with MOGAD.
Read it: mogproject.org/family-newsletter
@themogproject.bsky.socialLiving with MOGAD? We want to hear from you. 🩷🩵
The IMPACT Study is an anonymous 20–30 minute survey for ages 12–20 with MOGAD and parents or guardians of anyone 0–20 with MOGAD.
@taneuroldisord.bsky.socialWhat is the effect of #MOGAD on brain volume & networks in pediatric patients?
Shangru Li and colleagues investigated:
journals.sagepub.com/doi/full/10....
@taneuroldisord.bsky.socialWhat are the treatment patterns & access and burden of #MOGAD in China?
Check out this nationwide cross-sectional study by Yue Yu & colleagues:
journals.sagepub.com/doi/full/10....
@themogproject.bsky.socialThe 2026 MOGAD Patient Summit highlight reel is here! Thank you to everyone who joined us in Baltimore and online!
Watch: https://youtu.be/MF7zS5l5nek
Session recordings arrive on our YouTube channel in the coming month. Subscribe to catch them!
@thesumairafdn.bsky.socialNew consensus-based paper in @SclerosisAnd explores the current status of #NMOSD and #MOGAD management in #LATAM.
Main challenges: delayed diagnosis, misdiagnosis, unequal access, variable testing, low access to newer therapies.
Read the summary: www.sumairafoundation.org/summaries/nm...
@taneuroldisord.bsky.socialWhat is the efficacy & safety of the interleukin-6 receptor inhibitors #tocilizumab and #satralizumab in #MOGAD?
Aasim Ali & colleagues conducted a #SystematicReview and #MetaAnalysis to summarize the evidence:
journals.sagepub.com/doi/full/10....
@themogproject.bsky.socialNew MOGAD MRI review just published in JAMA Neurology — co-authored by 12 of our own MSAC members, including Dr. Eoin Flanagan, Dr. Michael Levy, Dr. Brenda Banwell & Dr. Jacqueline Palace. Proud of this team advancing MOGAD care. 🧠💗 #MOGAD
@jamaneurology.comIn #MOGAD, MRI lesions often resolve over time and asymptomatic radiological activity is rare, limiting the clinical utility of surveillance MRI compared with multiple sclerosis.
@thesumairafdn.bsky.social
@thesumairafdn.bsky.social🌴 Conozcan a nuestros valientes panelistas, pacientes y cuidadores! 🌺
Únanse a pacientes, cuidadores y familias de las comunidades #CIDP, #MG, #MOGAD y #NMOSD para un día de educación, conexión y apoyo.
¡26 de septiembre! tinyurl.com/TSFMiami2026ES
@thesumairafdn.bsky.social🌴 Meet our courageous patient & caregiver panelists at Miami Patient Day! 🌺
Join patients, caregivers & families from the #CIDP, #MG, #MOGAD & #NMOSD communities for a day of education, connection & support. Sept. 26!
Register: tinyurl.com/TSFMiami2026
@thesumairafdn.bsky.social🌎 New consensus review reveals major gaps in #NMOSD & #MOGAD care across LatAm: delayed diagnosis, misdiagnosis as MS, limited access to gold-standard antibody testing & unequal access to effective therapies. 2 priorities: better testing + better access.
www.msard-journal.com/article/S221...
@thesumairafdn.bsky.social💙 #MOGAD update: The FDA granted Priority Review to Genentech’s application for Enspryng® (satralizumab). In Phase III, it reduced relapse risk by 68%. If approved, it could be the first FDA-approved MOGAD treatment. Decision expected Jan. 10, 2027.
@pharmaphorum.bsky.social#Patients with a #rare #autoimmunedisease known as #MOGAD could be just a few months away from having the first approved treatment.
@thesumairafdn.bsky.social